Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.
Market Dynamics
Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.
Key features of the study:
This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics
The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Rivaroxaban Market, By Strength:
10 mg
15 mg
20 mg
Global Rivaroxaban Market, By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
Global Rivaroxaban Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Rivaroxaban Market, By Region:
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
Germany
U.K.
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
GCC
Israel
Rest of Middle East
Africa
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
North Africa
Central Africa
South Africa
Company Profiles
Janssen Pharmaceuticals Inc.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Bayer AG
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Strength
o Market Snippet, By Application
o Market Snippet, By Distribution Channel
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Industry Trends
o Regulatory Scenario
o Epidemiology
4. Global Rivaroxaban Market, By Product Type, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o 10 mg
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o 15 mg
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o 20 mg
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
5. Global Rivaroxaban Market, By Application, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Deep Vein Thrombosis Prophylaxis
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Pulmonary Embolism
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
6. Global Rivaroxaban Market, By Distribution Channel, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Hospitals Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
7. Global Rivaroxaban Market, By Regions, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, By Region, 2017 - 2026
o Regional Trends
o North America
o Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• U.S.
• Canada
o Europe
o Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• China
• Japan
• India
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o Middle East
o Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• GCC Countries
• Israel
• Rest of Middle East
o Africa
o Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• Northern Africa
• Central Africa
• South Africa
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Janssen Pharmaceuticals Inc.*
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Market Strategies
o Bayer AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 22 market data tables and 20 figures on "Rivaroxaban Market - Global forecast to 2026".
Request Discount 
Inquire Before Buy
